Discovery and Structure−Activity Relationships of Piperidinone- and Piperidine-Constrained Phenethylamines as Novel, Potent, and Selective Dipeptidyl Peptidase IV Inhibitors
作者:Zhonghua Pei、Xiaofeng Li、Thomas W. von Geldern、Kenton Longenecker、Daisy Pireh、Kent D. Stewart、Bradley J. Backes、Chunqiu Lai、Thomas H. Lubben、Stephen J. Ballaron、David W. A. Beno、Anita J. Kempf-Grote、Hing L. Sham、James M. Trevillyan
DOI:10.1021/jm061436d
日期:2007.4.1
Dipeptidyl peptidase IV (DPP4) inhibitors are emerging as a new class of therapeutic agents for the treatment of type 2 diabetes. They exert their beneficial effects by increasing the levels of active glucagon-like peptide-1 and glucose-dependent insulinotropic peptide, which are two important incretins for glucose homeostasis. Starting from a high-throughput screening hit, we were able to identify
二肽基肽酶IV(DPP4)抑制剂是作为治疗2型糖尿病的新型治疗剂而出现的。它们通过增加活性胰高血糖素样肽1和葡萄糖依赖性促胰岛素肽的水平来发挥其有益作用,这是葡萄糖稳态的两个重要降钙素。从高通量筛选开始,我们能够鉴定出一系列受哌啶酮和哌啶约束的苯乙胺作为新型DPP4抑制剂。优化的化合物是有效的,选择性的,并具有良好的药代动力学特征。